Market Overview

Adam Feuerstein Is A Skeptic Of Stem Cell Therapy

Share:

Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick.

TheStreet Senior Columnist Adam Feuerstein discussed Cytori Therapeutics Inc (NASDAQ: CYTX) on the show.

Overall, Feuerstein was skeptical of stem cell therapy companies.

“I think it’s a very difficult area of drug development, it has not shown much promise,” Feuerstein said.

The columnist pointed out that another stem cell related company, Athersys, Inc. (NASDAQ: ATHX), was “blowing up” Friday because its stroke study had failed.

“I feel like these companies don’t really have very much going on, Cytori being among those,” according to Feuerstein.

Cytori Therapeutics traded at $1.11, down 2.63 percent, while Athersys fell over 35 percent Friday to $1.41.

Check out the full interview below. Feuerstein comes in at about the one-hour mark:

Posted-In: Adam Feuerstein TheStreetExclusives Trading Ideas Interview

 

Related Articles (ATHX + CYTX)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals

Why This Trader Is Worried About Jazz Pharmaceuticals